BiotechTube

Troriluzole + Placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obsessive-Compulsive Disorder

Conditions

Obsessive-Compulsive Disorder

Trial Timeline

Dec 19, 2017 → Dec 8, 2025

NCT ID
NCT03299166

About Troriluzole + Placebo

Troriluzole + Placebo is a phase 2/3 stage product being developed by Biohaven for Obsessive-Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03299166. Target conditions include Obsessive-Compulsive Disorder.

What happened to similar drugs?

2 of 4 similar drugs in Obsessive-Compulsive Disorder were approved

Approved (2) Terminated (0) Active (2)
✅pregabalin + PlaceboPfizerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
🔄Troriluzole + PlaceboBiohavenPhase 3
🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04693351Phase 3Completed
NCT04641143Phase 3Completed
NCT03701399Phase 3Active
NCT03829241Phase 3Completed
NCT03299166Phase 2/3Completed

Competing Products

8 competing products in Obsessive-Compulsive Disorder

See all competitors
ProductCompanyStageHype Score
Bitopertin + Placebo + SSRIRochePhase 2
35
pregabalin + PlaceboPfizerApproved
43
Sertraline + Levetiracetam + PlaceboUCBPhase 2/3
30
Escitalopram + Placebo oral tabletLundbeckApproved
44
Valbenazine + PlaceboNeurocrine BiosciencesPhase 2
39
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 3
34
Nitrous Oxide + NitrogenBrain BiotechPhase 2
32